Renaissance Capital logo

IRTC News

US IPO Weekly Recap: Two deals flounder while one soars

FRTA

Three IPOs raised $495 million this week, led by iRhythm Technologies (IRTC), which popped 53% on its first day. The other two IPOs, CRISPR Therapeutics (CRSP) and Forterra (FRTA), priced below the range and closed the week down 1% and 6%, respectively. Forterra’s 8% drop on its first day was the eighth worst...read more

High-growth heart monitors: iRhythm Technologies prices upsized IPO above the range at $17

IRTC

iRhythm Technologies, which provides a device and analysis for detecting cardiac arrhythmias, raised $107 million in an upsized IPO by offering 6.3 million shares at $17, above the $13 to $15 range. It had originally planned to raise $75 million by offering 5.4 million shares. iRhythm Technologies plans to list on the Nasdaq under the symbol IRTC. J.P. Morgan and Morgan...read more

US IPO Week Ahead: 3 IPOs feature industrial pipes and high-growth health care

FRTA

Three IPOs are set to raise $518 million in the week ahead. LBO'd industrial pipe maker Forterra is by far the week's largest deal, while CRISPR Therapeutics will attempt to prove that gene editing is more than a pipe dream. High-growth heart monitoring company iRhythm Technologies plans to raise $75 million. A fourth deal, Full Spectrum, is still exploring its $15 million IPO on a...read more

Heart monitoring as a service: iRhythm Technologies sets terms for $75 million IPO

IRTC

iRhythm Technologies, which provides a device and analysis for detecting cardiac arrhythmias, announced terms for its IPO on Friday. The San Francisco, CA-based company plans to raise $75 million by offering 5.35 million shares at a price range of $13 to $15. Insiders intend to purchase $15 million worth of shares in the offering. At the midpoint of the proposed range, iRhythm...read more